- Home
- NJR vs AXSM Comparison
NJR vs AXSM Comparison
Compare NJR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NJR
- AXSM
- Stock Information
- Founded
- NJR 1922
- AXSM 2012
- Country
- NJR United States
- AXSM United States
- Employees
- NJR 1372
- AXSM N/A
- Industry
- NJR Oil/Gas Transmission
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- NJR Utilities
- AXSM Health Care
- Exchange
- NJR Nasdaq
- AXSM Nasdaq
- Market Cap
- NJR 4.5B
- AXSM 5.1B
- IPO Year
- NJR N/A
- AXSM 2015
- Fundamental
- Price
- NJR $44.28
- AXSM $100.69
- Analyst Decision
- NJR Hold
- AXSM Strong Buy
- Analyst Count
- NJR 6
- AXSM 16
- Target Price
- NJR $51.33
- AXSM $170.50
- AVG Volume (30 Days)
- NJR 583.5K
- AXSM 659.8K
- Earning Date
- NJR 08-05-2025
- AXSM 08-04-2025
- Dividend Yield
- NJR 4.06%
- AXSM N/A
- EPS Growth
- NJR 63.33
- AXSM N/A
- EPS
- NJR 4.14
- AXSM N/A
- Revenue
- NJR $2,072,804,000.00
- AXSM $432,157,000.00
- Revenue This Year
- NJR $6.93
- AXSM $62.84
- Revenue Next Year
- NJR $2.86
- AXSM $60.02
- P/E Ratio
- NJR $10.70
- AXSM N/A
- Revenue Growth
- NJR 20.48
- AXSM 72.16
- 52 Week Low
- NJR $41.68
- AXSM $72.02
- 52 Week High
- NJR $51.95
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- NJR 33.45
- AXSM 37.30
- Support Level
- NJR $43.80
- AXSM $99.39
- Resistance Level
- NJR $44.94
- AXSM $112.98
- Average True Range (ATR)
- NJR 0.58
- AXSM 3.33
- MACD
- NJR 0.01
- AXSM -0.76
- Stochastic Oscillator
- NJR 20.17
- AXSM 9.35
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.